- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Molnupiravir
Central Data Repository
Explore the Central Data Repository: Use the filters and keyword search box on the left to find relevant studies. As you refine your search, the map and study list will automatically update to reflect your selections. Selecting a study from the list will provide detailed information about the specific study in question. A full legend can be found here
{content}
Study list
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Antivirals
- Plitidepsin
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Dietary
- Lifestyle
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- Primary care
- Telemedicine
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Emergency department
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Molnupiravir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Remdesivir
- Molnupiravir
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- Monkeypox virus
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Emergency department
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Remdesivir
- Adults (18-64 years)
- Elderly (≥65 years)
- People at high risk of STIs
- Men who have sex with men
- PrEP users
- Primary care
- Non-hospital health centre
- STD/STI clinic
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Treponema pallidum
- Pharmacological intervention
- Antivirals
- PrEP-HIV
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Emergency department
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Adults (18-64 years)
- General population
- Hospital
- Non-hospital health centre
- Vaccination centre
- Monkeypox virus
- Blood sample
- Pharmacological intervention
- Vaccination
- MVA-BN
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- Monkeypox virus
- Adults (18-64 years)
- People at high risk of STIs
- Men who have sex with men
- Hospital
- Outpatient clinic
- Monkeypox virus
- Adults (18-64 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Adolescents (12-17 years)
- Emergency department
- SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Infants (<1 year)
- Children (1-11 years)
- Adolescents (12-17 years)
- Hospital
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Adenovirus
- Rhinovirus
- Human metapneumovirus
- Parainfluenza Virus
- Enterovirus
- Bordetella pertussis
- Seasonal coronavirus
- Bordetella parapertussis
- Chlamydia pneumoniae
- Mycoplasma pneumoniae
- Influenza-like illness/Acute respiratory infection
- Diagnostics
- Point of care tests
- Adults (18-64 years)
- Elderly (≥65 years)
- Community
- Arbovirus
- Chikungunya virus
- Vector-borne
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Remdesivir
- Molnupiravir
- Adults (18-64 years)
- Fragile population
- Immunocompromised host
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Remdesivir
- Sotrovimab
- Molnupiravir
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation